
Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week ® 2025
BUSINESS WIRE)-- Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, an investigational, once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), today announced it will present immunogenicity and biomarker analyses from its Phase 2 study, in participants with stage F2 and F3 fibrosis due to MASH. The results will be presented in a state-of-the-art lecture and poster at Digestive Disease Week (DDW) in San Diego, May 3-6, 2025. These findings further support the advancement of the efimosfermin clinical program to a Phase 3 pivotal study in 2025.
'Efimosfermin has demonstrated rapid and strong response across liver and cardiometabolic biomarkers, along with a favorable safety and tolerability profile. Its once-monthly dosing is expected to be a significant advantage for both prescribers and patients, providing confidence that efimosfermin could set a new standard in MASH treatment,' said Sophie Kornowski, CEO of Boston Pharmaceuticals. 'With our robust data, along with the commitment from our Board and a strong funding strategy, we aim to accelerate efimosfermin's development and begin enrolling patients in a Phase 3 study in F2 and F3 patients before the end of the year, followed by an F4 trial after planned discussions with regulators.'
The state-of-the-art oral presentation will showcase results from the Phase 2, randomized, placebo-controlled, 24-week treatment study in participants with biopsy-confirmed F2 and F3 MASH. The study showed significant improvements in histopathology, with 45.2% (p=0.038) of participants treated with efimosfermin 300mg achieving fibrosis improvement ≥1 stage without worsening of MASH compared to 20.6% in the placebo group, and MASH resolution without worsening of fibrosis in 67.7% of participants (p=0.002) versus 29.4% at 24 weeks. Efimosfermin also demonstrated extrahepatic benefits, including positive impacts on lipids and in participants with diabetes, clinically meaningful improvements in glycemic control. In this study, efimosfermin was generally well-tolerated, with low discontinuation rates due to adverse events, and an overall low incidence of gastrointestinal side effects and injection site reactions. Data to be presented will also highlight the favorable immunogenicity profile of efimosfermin.
Exploratory analyses of the phase 2 study of changes in biomarkers that identify at-risk MASH patients will be presented as a poster. These results strengthen the histopathology findings, demonstrating rapid and marked effects on biomarkers of steatosis, fibrosis, and liver injury, and supports the potential of efimosfermin as a once-monthly, disease-modifying therapeutic for the treatment of MASH.
'These analyses further support the Phase 2 study findings and provides the scientific community with the confidence to advance the development of efimosfermin as a potential therapy for patients with F2 and F3 fibrosis,' said Mazen Noureddin, M.D., M.H.Sc., lead investigator and Professor of Medicine at Houston Methodist Hospital, and Director of the Houston Research Institute. 'Based on these encouraging results, we expect to see continued progress as we evaluate findings across histology and non-invasive markers in patients with F2 and F3 MASH receiving efimosfermin treatment for up to 48 weeks.'
Details of Boston Pharmaceuticals' presentations are as follows:
Digestive Disease Week 2025
Oral Presentation Title:
Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24 Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Abstract Number:
723
Session:
State-of-the-Art Lecture: Update on MASLD Therapies Pipeline
Session Date, Time:
Monday, May 5, 2025, 10:00 a.m. – 11:30 a.m. PDT
Presentation Time:
11:05 a.m. – 11:20 a.m. PDT
Location:
6F
Presenter:
Matthew Bryant, PharmD, Vice President of Medical Affairs, Boston Pharmaceuticals
Expand
Poster Presentation Title:
Once-Monthly Efimosfermin Alfa Improves FAST and FIB-4 Composite Biomarker Scores for MASH Stage F2-F3 Fibrosis in a 24-Week Phase 2 Trial
Abstract Number:
Sa1504
Session:
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Session Date, Time:
Location:
Halls C-E
Presenter:
Rohit Loomba, M.D., MHSc, Professor of Medicine, Chief in the Division of Gastroenterology and Hepatology, and Director of MASLD Research Center at University of California, San Diego
Expand
About MASH
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a growing global epidemic fueled by the increasing prevalence of obesity and type 2 diabetes. It is estimated that MASH affects millions of people worldwide, including 17 million in the U.S., and is expected to increase by 63% by 2030. MASH is a progressive disease staged by the degree of fibrosis (scarring) in the liver and is closely associated with multiple cardiometabolic risk factors. Left untreated, MASH could lead to liver failure, liver cancer or death. In the U.S., MASH is now a leading cause of liver transplantation.
About efimosfermin alfa
Boston Pharmaceuticals' lead investigational agent, efimosfermin alfa (formerly BOS-580) is a once-monthly subcutaneous injectable of a long-acting variant of human fibroblast growth factor 21 (FGF21) that regulates various metabolic pathways to decrease liver fat and ameliorate liver inflammation and damage in patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The Phase 2 clinical development program of efimosfermin is continuing with an open-label extension in F2 and F3 MASH patients, providing an additional 24 weeks of treatment to assess long-term safety and efficacy up to 48 weeks. Boston Pharmaceuticals also plans to initiate a supplemental study in F4 MASH to further expand and enrich the data set for this patient population.
About Boston Pharmaceuticals
Boston Pharmaceuticals, a portfolio company of B-FLEXION, is a clinical-stage biopharmaceutical company that leverages an experienced and committed drug development team to advance a portfolio of highly differentiated therapies that may address important unmet medical needs in serious liver diseases, with MASH as the focus of its lead asset. The Company has significant expansion opportunities through its portfolio of promising drug development candidates that were acquired through partnerships with proven, innovative biotechnology and pharmaceutical companies. Boston Pharmaceuticals applies rigorous decision-making to advance programs to deliver differentiated medicines to patients in need of new options while creating value for all parties involved in the journey.
For more information, please visit www.bostonpharmaceuticals.com and follow us on LinkedIn.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. This communication, other than statements of historic fact, are forward-looking statements.
Boston Pharmaceutical's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful. Boston Pharmaceuticals does not undertake to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this presentation except as required by law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
17 minutes ago
- Business Wire
AI Time Platform Laurel Raises $100 Million to Transform the Professional Services Industry
SAN FRANCISCO--(BUSINESS WIRE)--Laurel, the world's first AI Time platform, today announced it has raised $100 million in Series C funding led by IVP, with participation from GV (Google Ventures). Laurel will leverage this investment to scale its AI time platform and accelerate to solve what it calls the 'time intelligence challenge"—the inability for knowledge industries to accurately map time to business outcomes. In the age of AI, quantifying and understanding human capital goes from a 'nice to have' to a 'cannot exist without' for enterprises. In addition to IVP and GV, new investors in the round, which consists of primary and secondary funding, also include: 01.a (created by former CEO and COO of Twitter & CRO of Facebook), DST Global, Kevin Weil (CPO @ OpenAI), Alexis Ohanian, Vladimir Fedorov (CTO @ GitHub), Arash Ferdowsi (co-founder of Dropbox), and Hans Tung. These investors join returning investors ACME, Anthos, Gokul Rajaram, AIX Ventures, and Marc Benioff's TIME Ventures. The funding comes as Laurel experiences rapid adoption among enterprise professional services firms like Ernst & Young, Grant Thornton, Freshfields, and Crowell & Moring. Over the last 12 months, Laurel grew ARR +300% at double-digit scale, increased usage by +500%, and works with +100 of the top legal, accounting, and consulting firms across US, UK, EU, Australia, and Canada. Laurel's AI Time platform, now leveraged by hundreds of the world's top enterprise professional service firms, uses AI to automatically categorize, describe, and analyze how professionals spend their time on admin work. The platform's ability to connect time data with business outcomes has proven transformative for firms looking to maximize profits, allocate their resources effectively, and understand exactly what workflows to apply AI to and what agents to automate. Customers using the company's AI-native time platform report profit increases between 4-11%—driven by an additional 28 billable minutes per day per professional, and increased realization of 1-4%. Laurel's ROI methodology has been independently audited and validated by a Big-4 Firm. The platform currently processes over $5B in gross market value for its customers, and +$360M of that amount is net-new value attributable to Laurel. In addition, Laurel saves its professionals up to 80% in time recording, freeing them to work on high-leverage work. 'Laurel uniquely delivers value across lawyers, clients, finance, and marketing by streamlining time capture, enriching narratives, and accelerating accurate billing,' says Reed Cunningham, Chief Innovation Officer at global law firm Reed Smith. 'As firms assess the impact of AI and fixed fees, gaining granular intelligence with less effort is essential to redefining value within a firm and for its clients.' 'I've seen first-hand how Laurel can transform our approach to time intelligence. What used to be a manual process of time-keeping and entry is now significantly technology enabled,' says Matt Newnes, Partner and Tax Transformation leader at Ernst & Young. 'Laurel doesn't just help our people to capture time that they spend on work more comprehensively; it helps us to understand much more about how our teams work allowing us to identify best practices to help ensure we always drive the best outcomes for our clients. It has proven to be one of our most impactful AI investments, delivering measurable results while laying the foundation for broader transformation initiatives.' Automating time is Laurel's first step. Laurel's AI platform turns its proprietary data around work and time to address the #1 business problem impacting knowledge industries: operating without visibility into their supply chain. 'Nobody has ever mapped the input of time to the output of outcomes. Industries like legal and accounting are best at understanding their input (time), but still struggle to price value. On the flip side, industries like consulting and financial services understand value, but operate blind to the true cost of creation. While all other industries have been obsessed about optimizing their supply chain, the supply chain of knowledge work—which represents over 50% of Global GDP—has never been surfaced. This funding helps us solve this fundamental challenge while giving firms the data foundation they need to deploy AI strategically. We're not just automating time—we're creating the time intelligence layer that will transform how all knowledge industries operate," says Ryan Alshak, founder and CEO of Laurel. "Laurel has identified one of the largest efficiency gaps in the modern economy, one I understand deeply as a former CFO of a public company. Professional services represent trillions in global economic activity, yet these firms operate without basic visibility into their core resource – time. By solving the time intelligence challenge, Laurel creates a platform for broader AI transformation. As these industries invest heavily in AI over the next five years, Laurel's data foundation becomes essential infrastructure that truly tracks the ROI of AI. The market opportunity is massive, and Laurel's unique position makes them the clear leader in this space," says Ajay Vashee, General Partner at IVP. 'Laurel is creating the enterprise intelligence layer for knowledge work that leverages timekeeping as a product wedge,' said Frederique Dame, General Partner at GV. 'By capturing and organizing the full lifecycle of how professionals spend their time, Laurel unlocks a new class of data that makes work itself measurable, optimizable, and automatable. The goal isn't just better time tracking, it's building the data foundation for AI-powered workflows, predictive resourcing, and strategic insights.' Transforming How Knowledge Industries Understand and Optimize Work While manufacturing companies know exactly how much it costs to produce a car down to the penny, and retail businesses track inventory with precision, professional services firms have historically operated without understanding their most critical resource: human capital. Both the outcomes of the work itself and the time it takes to produce it. As a result, organizations are operating blind on what the biggest impact for AI is across their companies, and how to point people to highest value tasks (like Business Development, Relationship Management, and first principles strategic thinking). As knowledge industries plan to spend over $1 trillion on AI in the next five years, Laurel's time intelligence platform ensures these investments target the highest-impact opportunities. Key customer results include: Average recovery of 28+ billable minutes per professional per day 4-11% increase in overall firm profitability 80%+ reduction in time spent on manual time entry Real-time visibility into project profitability and resource utilization 'While Laurel is unique in that it is AI that generates profits, the reason everyone at Laurel cares so much about solving this problem is because people waste so much time at work, and the only way to solve this at scale is to deeply understand where that time is going,' says Alshak. 'And we're starting with professional services because that will give us the human-in-the-loop required to create the world's first-ever agentic timesheet. The average knowledge worker works 9 hours a day, but only adds leverage for 3. That is 3 hours a day we're doing work that should be done by agents, and 3 hours a day we're doing work that nobody should do. That is our opportunity set – 6.4 billion years currently being spent by knowledge workers on tasks humans no longer need to do. That is our opportunity.' About Laurel Laurel is the world's first AI Time platform for professional services firms. The company's AI transforms how organizations track, analyze, describe, and optimize their most valuable resource: time. By automating work time and connecting time data to business outcomes, Laurel enables firms to increase profitability, improve client delivery, and make data-driven strategic decisions. Founded in 2018, Laurel serves many of the world's largest accounting, consulting and law firms. For more information, visit About IVP IVP supercharges growth in breakout companies, converting momentum into market dominance. One of the original venture firms on Sand Hill Road, IVP partners with companies that define their eras—from Slack, Crowdstrike and Coinbase to Perplexity, Abridge, Glean and Chainguard—before the world truly appreciated them. Each year, IVP invests in just a dozen breakout founders ready to scale from millions to hundreds of millions in revenue and expand from one market to many. We've guided market leaders through cycles and storms, unlocking pivotal growth by activating the right expertise at the moments founders need it. With 130+ IPOs out of 400 investments, IVP helps ambitious founders defy limits, command industries and cement their place at the top.
Yahoo
33 minutes ago
- Yahoo
DEEPX and Wind River Collaborate to Advance Mission-Critical Edge AI Applications
SEOUL, South Korea & ALAMEDA, Calif., June 10, 2025--(BUSINESS WIRE)--DEEPX, a pioneering on-device AI semiconductor company, and Wind River, a global leader in delivering software for the intelligent edge, have collaborated on a hardware and software solution for next-generation edge AI. The partnership combines DEEPX's on-device AI semiconductors with Wind River's VxWorks® real-time operating system (RTOS) and Wind River® Helix™ Virtualization Platform to help advance solutions for mission-critical industries such as aerospace, defense, industrial, and robotics. "Edge AI is on a path to unlock incredible opportunities across a diverse range of industries. Together with Wind River's long heritage in software for markets that are highly dependent on safety, security, reliability, and edge expertise, DEEPX can provide customers with innovative edge AI platforms that deliver exceptional performance, cost, and power efficiency," said Lokwon Kim, CEO, DEEPX. "The growth of real-time physical AI is creating immense potential for mission-critical environments while also presenting new, complex challenges. The collaboration between DEEPX's advanced AI semiconductors and Wind River's proven edge technologies will help advance AI to deliver tremendous outcomes across applications and industries," said Avijit Sinha, Senior Vice President, Strategy and Global Business Development, Wind River. With the enablement of DEEPX's neural processing units (NPUs) on Wind River technologies, companies can easily add accelerated AI to their real-time or edge systems, at lower cost. DEEPX and Wind River work to deliver a pre-validated solution stack that addresses safety and security issues, helping companies significantly reduce complexity and development cycles. A leader in on-device AI, DEEPX develops advanced AI semiconductors that optimize performance, reduce power consumption, and enhance cost efficiency across various industries, including smart camera modules, smart mobility, smart factories, consumer electronics, smart cities, surveillance systems, and AI servers. DEEPX's cutting-edge AI chips are engineered for maximum efficiency and effortless integration into any device. Market-leading VxWorks is the industry's most trusted and widely deployed RTOS for mission-critical systems that must be secure and safe. The first commercial RTOS to support Open Container Initiative (OCI)–compliant containers, VxWorks enables companies to rapidly deploy new software-defined capabilities. Helix Platform is a hypervisor solution that enables engineering teams to consolidate multiple systems onto a single high-performance embedded system. It streamlines safety certification, reduces project risk, and accelerates time-to-market. About DEEPX DEEPX is leading the next-generation semiconductor market with its innovative AI technology and global competitiveness. The company has filed over 300 patents worldwide and registered more than 70, securing world-class proprietary AI semiconductor technology assets. DEEPX has been listed in the EE Times "Silicon 100" for two consecutive years and was named "Best Company in the AI Semiconductor Industry" by U.S. market research firm Frost & Sullivan. DEEPX continues solidifying its position as a key player in the AI semiconductor market through its global achievements and recognition for its innovation and technological leadership. About Wind River Wind River is a global leader in delivering software for the intelligent edge. For more than four decades, the company has been an innovator and pioneer, powering billions of devices and systems that require the highest levels of security, safety, and reliability. Wind River software and expertise are accelerating digital transformation across industries including automotive, aerospace, defense, industrial, medical, and telecommunications. The company offers a comprehensive portfolio supported by world-class global professional services and support and a broad partner ecosystem. To learn more, visit Wind River at Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners. View source version on Contacts MEDIA CONTACT Jenny SuhWind
Yahoo
33 minutes ago
- Yahoo
Backing the Future of Global Biotech: Reynold Lemkins' Strategy Across Borders and Stages
HONG KONG, June 10, 2025--(BUSINESS WIRE)--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broader strategy of supporting science-driven, late-stage companies with scalable market potential—particularly those operating at the convergence of AI, therapeutics, and Asia-Pacific commercialization. "Our approach focuses on more than capital—we provide strategic insight and cross-border connectivity to help companies scale," said Kris Haoran Liu, President and Chief Investment Officer at Reynold Lemkins Group. "Biotech firms entering public markets need partners who understand both the science and the structure of global growth." With Asia playing an increasingly pivotal role in global healthcare, Reynold Lemkins sees a growing need for capital strategies that link scientific innovation with scalable regional execution. At the same time, the firm closely tracks trends in the U.S. and other mature markets, where biotech companies are navigating longer paths to liquidity and require strategic partners with global reach. Reynold Lemkins positions itself at this intersection—bridging East and West, public and private markets—to support companies shaping the next era of patient-centered care. To learn more, visit follow us on LinkedIn, or explore our insights on Medium. View source version on Contacts Reynold Lemkins Groupreynoldlemkins@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data